Profil
Kelly O’Brien Wilson currently works at Forte Animal Health, Inc., as Director from 2020 and Biostax Corp., as Chief Operating Officer from 2022.
Ms. Wilson also formerly worked at Biostax Corp., as CTO & Director-Human Resources from 2015 to 2020, Biostax Corp., as Chief Executive & Operating Officer in 2023, and Cytocom, Inc., as Chief Technology & Information Officer from 2016 to 2020.
Ms. Wilson received her undergraduate degree and graduate degree from the University of Central Florida.
Postes actifs de Kelly Wilson
| Sociétés | Poste | Début |
|---|---|---|
| BIOSTAXPAR | Directeur des opérations | 01/08/2022 |
Forte Animal Health, Inc. | Directeur/Membre du Conseil | 01/12/2020 |
Anciens postes connus de Kelly Wilson
| Sociétés | Poste | Fin |
|---|---|---|
| BIOSTAXPAR | Directeur Général | 25/07/2023 |
| BIOSTAXPAR | Directeur Technique/Scientifique/R&D | 01/04/2020 |
Cytocom, Inc. /Old/
Cytocom, Inc. /Old/ BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops novel small molecule immunotherapies | Directeur Technique/Scientifique/R&D | 01/04/2020 |
Formation de Kelly Wilson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
University of Central Florida
University of Central Florida Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biostax Corp.
Biostax Corp. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical & biotechnology products | Health Technology |
Cytocom, Inc. /Old/
Cytocom, Inc. /Old/ BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops novel small molecule immunotherapies | Health Technology |
Forte Animal Health, Inc. | Process Industries |
















